Literature DB >> 10444430

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

D D Lazarus1, A T Destree, L M Mazzola, T A McCormack, L R Dick, B Xu, J Q Huang, J W Pierce, M A Read, M B Coggins, V Solomon, A L Goldberg, S J Brand, P J Elliott.   

Abstract

A new model of cachexia is described in which muscle protein metabolism related to the ubiquitin-proteasome pathway was investigated. Cloning of the colon-26 tumor produced a cell line, termed R-1, which induced cytokine (noninterleukin-1beta, interleukin-6 and tumor necrosis factor-alpha)-independent cachexia. Implantation of R-1 cells in mice elicited significant (20-30%) weight loss and decreased blood glucose by 70%, and adipose tissue levels declined by 95% and muscle weights decreased by 20-25%. Food intake was unaffected. The decrease in muscle weight reflected a decline in insoluble, but not soluble, muscle protein that was associated with a significant increase in net protein degradation. The rate of ubiquitin conjugation of proteins was significantly elevated in muscles of cachectic mice. Furthermore, the proteasome inhibitor lactacystin blocked the increase in protein breakdown but had no significant effect on proteolysis. Several markers of the ubiquitin-proteasome pathway, E2(14k) mRNA and E2(14k) protein and ubiquitin-protein conjugates, were not elevated. Future investigations with this new model should gain further insights into the mechanisms of cachexia and provide a background to evaluate novel and more efficacious therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444430     DOI: 10.1152/ajpendo.1999.277.2.E332

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  19 in total

Review 1.  The cancer anorexia/weight loss syndrome: therapeutic challenges.

Authors:  Karin F Giordano; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

2.  The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia.

Authors:  Andrea Bonetto; Joseph E Rupert; Rafael Barreto; Teresa A Zimmers
Journal:  J Vis Exp       Date:  2016-11-30       Impact factor: 1.355

3.  Glucose regulates protein catabolism in ras-transformed fibroblasts through a lysosomal-dependent proteolytic pathway.

Authors:  C Tournu; A Obled; M P Roux; M Ferrara; S Omura; D M Béchet
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 4.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

Review 5.  Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.

Authors:  Megan E Rosa-Caldwell; Dennis K Fix; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2019-11-14

6.  Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia.

Authors:  Raymond D Devine; Sabahattin Bicer; Peter J Reiser; Markus Velten; Loren E Wold
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-19       Impact factor: 4.733

7.  A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.

Authors:  Danielle N Seto; Susan C Kandarian; Robert W Jackman
Journal:  J Biol Chem       Date:  2015-06-19       Impact factor: 5.157

8.  Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.

Authors:  Aminah Jatoi; Steven R Alberts; Nathan Foster; Roscoe Morton; Patrick Burch; Margaret Block; Phuong L Nguyen; John Kugler
Journal:  Support Care Cancer       Date:  2005-03-10       Impact factor: 3.603

9.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

10.  Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma.

Authors:  Mary Ann Honors; Kimberly P Kinzig
Journal:  Horm Cancer       Date:  2013-10-08       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.